Clinical Trials Sponsored by Cougar Biotechnology, Inc.

Total 405 results

AVM Biotechnology Inc
Medpace, Inc.

Recruiting

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies (OPAL)

Lymphoid Malignancies

United States
BRIM Biotechnology Inc.
ORA, Inc.

Completed

Safety and Efficacy of BRM421 for Dry Eye Syndrome Treatment

Dry Eye Syndrome

United States
ImStem Biotechnology
Rho, Inc.

Recruiting

A Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of IMS001 in Subjects With Multiple Sclerosis

Multiple Sclerosis

United States
GlaxoSmithKline
Vir Biotechnology, Inc.

Terminated

Pharmacokinetics, Pharmacodynamics, and Safety of Single-dose Sotrovimab in High-risk Pediatric Participants With Mild to Moderate COVID-19 (COMET-PACE)

COVID-19

United States
Vir Biotechnology, Inc.
GlaxoSmithKline

Completed

Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19 (COMET-PEAK)

Covid19

United States, Canada, Italy, Korea, Republic of, Spain
Lixte Biotechnology Holdings, Inc.

Unknown

A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes

United States
Blue Lake Biotechnology Inc.

Completed

Phase 1 Study of BLB-201 Vaccine in Healthy Young and Older Adults

Respiratory Syncytial Virus Infections

United States
Vir Biotechnology, Inc.
GlaxoSmithKline

Completed

A Study to Investigate the PK, Safety, and Tolerability of Sotrovimab vs Placebo Administered IV or IM in Japanese and Caucasian Participants

Covid19

United States
Blue Lake Biotechnology Inc.

Recruiting

A Study of BLB-201 RSV Vaccine in Infants and Children

Respiratory Syncytial Virus Infections

United States
Vir Biotechnology, Inc.
GlaxoSmithKline

Recruiting

Relative Bioavailability, Safety, and Tolerability of Single-dose Sotrovimab Injection in Adults (COSMIC) (COSMIC)

Covid19

United States
Vir Biotechnology, Inc.
GlaxoSmithKline

Terminated

Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19.

Covid19

United States, France, Ukraine
Vir Biotechnology, Inc.
GlaxoSmithKline

Completed

VIR-7831 for the Early Treatment of COVID-19 in Outpatients (COMET-ICE)

Covid19

United States, Canada, Spain, Austria, Brazil, Peru, United Kingdom
Lixte Biotechnology Holdings, Inc.

Completed

Phase I Study of LB-100 With Docetaxel in Solid Tumors

Neoplasms | Cancer | Tumors

United States
Ocular Therapeutix, Inc.

Recruiting

An Observational, Qualitative Study Assessing Eye Drop Administration

Ocular Injury

United States
Ocular Therapeutix, Inc.

Terminated

A Human Factors Study to Evaluate a Novel Intracanalicular Insertion Device in Healthy Subjects

Healthy

United States
Ocular Therapeutix, Inc.

Active, not recruiting

CLN-0046: Treatment of AMD Subjects With OTX-TKI

Neovascular Age-related Macular Degeneration

Australia
Ocular Therapeutix, Inc.

Completed

A Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Allergic Conjunctivitis

Allergic Conjunctivitis

United States
Ocular Therapeutix, Inc.

Completed

I-ZIP Ocular Bandage Pivotal Study

Cataract

United States
Ocular Therapeutix, Inc.

Completed

ReSure Sealant Pivotal Study

Cataract Surgery Incision Leak

United States
Ocular Therapeutix, Inc.

Active, not recruiting

Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy

Non-proliferative Diabetic Retinopathy

United States
Ocular Therapeutix, Inc.

Completed

Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-CSI in Subjects With Dry Eye Disease.

Dry Eye Disease

United States
Ocular Therapeutix, Inc.

Completed

To Assess the Efficacy and Safety of OTX-DED for the Short-term Treatment of Signs and Symptoms of Dry Eye Disease

Dry Eye

United States
Ocular Therapeutix, Inc.

Completed

Phase II Study Evaluating Safety/Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery

Ocular Inflammation and Pain

United States
Ocular Therapeutix, Inc.

Completed

Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHT

Ocular Hypertension | Open Angle Glaucoma

United States
Ocular Therapeutix, Inc.

Completed

Phase 3 Study Evaluating Safety and Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery

Post Ocular Surgical Inflammation and Pain

United States
Ocular Therapeutix, Inc.

Completed

Phase 2b Study Evaluating Safety and Efficacy of OTX-TP Compared to Timolol Drops in the Treatment of Subjects With Open Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

United States
Ocular Therapeutix, Inc.

Completed

Multi-Arm Feasibility Study Evaluating OTX-TP Compared to Timolol in Treatment of Subjects With Open Angle Glaucoma

Glaucoma

South Africa
Ocular Therapeutix, Inc.

Completed

ReSure Sealant Post Approval Study (Clinical PAS)

Adverse Events
Ocular Therapeutix, Inc.

Unknown

Non-Significant Risk Feasibility Study to Assess Retention and Replacement of the OTX Punctum Plug

Healthy Subjects
NSABP Foundation Inc
Puma Biotechnology, Inc.

Completed

Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

Breast Cancer

United States, Canada, Puerto Rico, Italy, Spain
NSABP Foundation Inc
Puma Biotechnology, Inc.

Completed

A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer

Breast Cancer

United States
NSABP Foundation Inc
Puma Biotechnology, Inc.

Active, not recruiting

Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status

Metastatic Colorectal Cancer

United States
Ocular Therapeutix, Inc.

Completed

A Study Assessing the Safety and Efficacy of Dextenza® for the Treatment of Ocular Pain and Inflammation Following Surgery for Pediatric Cataract

Cataract

United States
Ocular Therapeutix, Inc.

Active, not recruiting

OTX-DED for the Short-term Treatment of the Symptoms of Dry Eye Disease (DED)

Eye Diseases | Dry Eye Syndromes

United States
Ocular Therapeutix, Inc.

Completed

Study Evaluating the Treatment of OTX-TKI for Subjects With Neovascular Age-related Macular Degeneration

Neovascular Age-Related Macular Degeneration

United States
Ocular Therapeutix, Inc.

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patients With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT)

Ocular Hypertension | Open Angle Glaucoma

United States
Ocular Therapeutix, Inc.

Completed

A Study to Evaluate the Long Term Safety of OTX-TP (Sustained Release Travoprost) Intracanalicular Insert

Open Angle Glaucoma and Ocular Hypertension

United States
Ocular Therapeutix, Inc.

Completed

CLN-0045: Safety, and Efficacy of OTX-TIC in Participants With Open Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open Angle Glaucoma

United States
Ocular Therapeutix, Inc.

Withdrawn

OTX-14-002: Device Exposure Registry

Endophthalmitis
Ocular Therapeutix, Inc.

Completed

OTX-14-003: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocular Inflammation and Pain After Cataract Surgery

Post-Surgical Ocular Pain | Post-Surgical Ocular Inflammation
Ocular Therapeutix, Inc.

Completed

OTX-15:003: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocular Inflammation and Pain After Cataract Surgery

Post-Surgical Ocular Pain | Post-Surgical Ocular Inflammation
Ocular Therapeutix, Inc.
ORA, Inc.

Completed

OTX-14-006: A Phase 2 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Dry Eye

Dry Eye
Ocular Therapeutix, Inc.
ORA, Inc.

Completed

OTX-14-007: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis

Chronic Allergic Conjunctivitis
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

SENL101 Autologous T Cell Injection in Adults With Relapsed or Refractory CD7+ Hematolymphoid Malignancies

Lymphoma, T-Cell | T-ALL

China
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

China
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

Anti-PD-L1 Armored Anti-CD22 CAR-T/CAR-TILs Targeting Patients With Solid Tumors

Sarcoma | Cervical Cancer | NSCLC | Solid Tumor, Adult

China
Beijing Health Guard Biotechnology, Inc

Active, not recruiting

A Phase III Trial Evaluates the Efficacy, Immunogenicity and Safety Profile of HPV Vaccine

Human Papillomavirus Infection

China
Hebei Senlang Biotechnology Inc., Ltd.

Unknown

Safety and Efficacy Study of CD22 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia

B-ALL

China
Shanghai Longyao Biotechnology Inc., Ltd.

Unknown

The Clinical Study of CD19 UCAR-T Cells in Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL)

B-cell Acute Lymphoblastic Leukemia (B-ALL) | Safety and Efficacy of CD19 UCAR-T Cells

China
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

the Safety and Efficacy of SENL103 Autologous T Cell Injection

Multiple Myeloma

China

3

Subscribe